Indications for staging laparoscopy in pancreatic cancer

HPB

Volumn 18, Issue 1, 2016, Pages 13-20

  De Rosa, Antonella ^a   Cameron, Iain C ^a   Gomez, Dhanwant ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FERRITIN; LACTATE DEHYDROGENASE; TUMOR MARKER;

ALGORITHM; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE MARKER; HUMAN; JAUNDICE; LAPAROSCOPY; NEUTROPHIL LYMPHOCYTE RATIO; PAIN; PANCREAS CANCER; PHYSICAL PERFORMANCE; PREDICTION; PREDICTIVE VALUE; REVIEW; SENSITIVITY AND SPECIFICITY; STAGING LAPAROSCOPY; THROMBOCYTE COUNT; TREATMENT INDICATION; TUMOR LOCALIZATION; TUMOR VOLUME; WEIGHT REDUCTION; BLOOD; CLINICAL PATHWAY; DIAGNOSTIC IMAGING; PANCREATIC NEOPLASMS; PATHOLOGY; PATIENT SELECTION; PROCEDURES; X-RAY COMPUTED TOMOGRAPHY;

ALGORITHMS; CA-19-9 ANTIGEN; CRITICAL PATHWAYS; HUMANS; LAPAROSCOPY; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 84976400655     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1016/j.hpb.2015.10.004     Document Type: Review

References (75)

1. 1 Takai, S., Satoi, S., Toyokawa, H., Yanagimoto, H., Sugimoto, N., Tsuji, K., et al. Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas: a retrospective, single-institution experience. Pancreas 26 (2003), 243–249.
2. 2 Yeo, C.J., Cameron, J.L., Lillemoe, K.D., Sohn, T.A., Campbell, K.A., Sauter, P.K., et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 236 (2002), 355–366 discussion 366–358.
3. 3 Lim, J.E., Chien, M.W., Earle, C.C., Prognostic factors following curative resection for pancreatic adenocarcinoma – a population-based, linked database analysis of 396 patients. Ann Surg 237 (2003), 74–85.
4. 4 Pedrazzoli, S., DiCarlo, V., Dionigi, R., Mosca, F., Pederzoli, P., Pasquali, C., et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas - a multicenter, prospective, randomized study. Ann Surg 228 (1998), 508–514.
5. 5 Bipat, S., Phoa, S., van Delden, O.M., Bossuyt, P.M.M., Gouma, D.J., Lameris, J.S., et al. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma – a meta-analysis. J Comput Assisted Tomogr 29 (2005), 438–445.
6. 6 Pisters, P.W., Lee, J.E., Vauthey, J.N., Charnsangavej, C., Evans, D.B., Laparoscopy in the staging of pancreatic cancer. Br J Surg 88 (2001), 325–337 England.
7. 7 Vargas, R., Nino-Murcia, M., Trueblood, W., Jeffrey, R.B., MDCT in pancreatic adenocarcinoma: prediction of vascular invasion and resectability using a multiphasic technique with curved planar reformations. Am J Roentgenol 182 (2004), 419–425.
8. 8 Stefanidis, D., Grove, K.D., Schwesinger, W.H., Thomas, C.R., The current role of staging laparoscopy for adenocarcinoma of the pancreas: a review. Ann Oncol 17 (2006), 189–199.
9. 9 Camacho, D., Reichenbach, D., Duerr, G.D., Venema, T.L., Sweeney, J.F., Fisher, W.E., Value of laparoscopy in the staging of pancreatic cancer. JOP J Pancreas 6 (2005), 552–561.
10. 10 Conlon, K.C., Brennan, M.F., Laparoscopy for staging abdominal malignancies. Adv Surg 34 (2000), 331–350.
11. 11 Brockmann, J., Emparan, C., Hernandez, C.A., Sulkowski, U., Dietl, K.H., Menzel, J., et al. Gallbladder bile tumor marker quantification for detection of pancreato-biliary malignancies. Anticancer Res 20 (2000), 4941–4947.
12. 12 Kim, H.J., Kim, M.H., Myung, S.J., Lim, B.C., Park, E.T., Yoo, K.S., et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol 94 (1999), 1941–1946 United States.
13. 13 Ritts, R.E., Pitt, H.A., CA 19-9 in pancreatic cancer. Surg Oncol Clin N Am 7 (1998), 93–101.
14. 14 Mann, D.V., Edwards, R., Ho, S., Lau, W.Y., Glazer, G., Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 26 (2000), 474–479.
15. 15 Kang, C.M., Kim, J.Y., Choi, G.H., Kim, K.S., Choi, J.S., Lee, W.J., et al. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res 140 (2007), 31–35.
16. 16 vandenBosch, R.P., vanEijck, C.H.J., Mulder, P.G.H., Jeekel, J., Serum CA19-9 determination in the management of pancreatic cancer. Hepato-Gastroenterology 43 (1996), 710–713.
17. 17 Yasue, M., Sakamoto, J., Teramukai, S., Morimoto, T., Yasui, K., Kuno, N., et al. Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic-cancer. Pancreas 9 (1994), 735–740.
18. 18 Ong, S.L., Garcea, G., Thomasset, S.C., Mann, C.D., Neal, C.P., Abu Amara, M., et al. Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma. J Gastrointest Surg 12 (2008), 1068–1073.
19. 19 Fujioka, S., Misawa, T., Okamoto, T., Gocho, T., Futagawa, Y., Ishida, Y., et al. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. J Hepato-Biliary-Pancreatic Surg 14 (2007), 539–544.
20. 20 Mehta, J., Prabhu, R., Eshpuniyani, P., Kantharia, C., Supe, A., Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies. Trop Gastroenterol Off J Dig Dis Found 31 (2010), 190–194.
21. 21 Koenigsrainer, I., Zieker, D., Symons, S., Horlacher, K., Koenigsrainer, A., Beckert, S., Do patient- and tumor-related factors predict the peritoneal spread of pancreatic adenocarcinoma?. Surg Today 44 (2014), 260–263.
22. 22 Kilic, M., Gocmen, E., Tez, M., Ertan, T., Keskek, M., Koc, M., Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer. Can J Surg 49 (2006), 241–244.
23. 23 Schlieman, M.G., Ho, H.S., Bold, R.J., Utility of tumor markers in determining resectability of pancreatic cancer. United States Arch Surg 138 (2003), 951–955 discussion 955–956.
24. 24 Zhang, S., Wang, Y.-M., Sun, C.-D., Lu, Y., Wu, L.-Q., Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. World J Gastroenterol 14 (2008), 3750–3753.
25. 25 Cappelli, G., Paladini, S., D'Agata, A., Tumor markers in the diagnosis of pancreatic carcinoma. Tumori 85 (1999), S19–S21.
26. 26 Civardi, G., Cerri, L., Cavanna, L., Fornari, F., Distasi, M., Binelli, F., Diagnostic-accuracy of a new tumor serologic marker, CA 19-9-comparison with CEA. Tumori 72 (1986), 621–624.
27. 27 Delfavero, G., Fabris, C., Plebani, M., Panucci, A., Piccoli, A., Perobelli, L., et al. CA-19-9 and carcinoembryonic antigen in pancreatic-cancer diagnosis. Cancer 57 (1986), 1576–1579.
28. 28 Lundin, J., Roberts, P.J., Kuusela, P., Haglund, C., The prognostic value of preoperative serum levels of CA-19-9 and CEA in patients with pancreatic-cancer. Br J Cancer 69 (1994), 515–519.
29. 29 Kim, Y.C., Kim, H.J., Park, J.H., Park, D.I., Cho, Y.K., Sohn, C.I., et al. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?. J Gastroenterol Hepatol 24 (2009), 1869–1875 Australia.
30. 30 Vollmer, C.M., Drebin, J.A., Middleton, W.D., Teefey, S.A., Linehan, D.C., Soper, N.J., et al. Utility of staging laparoscopy in subsets of peripancreatic and biliary malignancies. Ann Surg 235 (2002), 1–7.
31. 31 Menack, M.J., Spitz, J.D., Arregui, M.E., Staging of pancreatic and ampullary cancers for resectability using laparoscopy with laparoscopic ultrasound. Surg Endoscopy-Ultrasound Interventional Tech 15 (2001), 1129–1134.
32. 32 Karachristos, A., Scarmeas, N., Hoffman, J.P., CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer. J Gastrointest Surg 9 (2005), 1286–1292.
33. 33 Maithel, S.K., Maloney, S., Winston, C., Goenen, M., D'Angelica, M.I., DeMatteo, R.P., et al. Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol 15 (2008), 3512–3520.
34. 34 Connor, S., Bosonnet, L., Alexakis, N., Raraty, M., Ghaneh, P., Sutton, R., et al. Serum CA19-9 measurement increases the effectiveness of staging laparoscopy in patients with suspected pancreatic malignancy. Dig Surg 22 (2005), 80–85.
35. 35 Halloran, C.M., Ghaneh, P., Connor, S., Sutton, R., Neoptolemos, J.P., Raraty, M.G.T., Carbohydrate antigen 19.9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy. Br J Surg 95 (2008), 453–459.
36. 36 Thomson, B.N.J., Parks, R.W., Redhead, D.N., Welsh, F.K.S., Madhavan, K.K., Wigmore, S.J., et al. Refining the role of laparoscopy and laparoscopic ultrasound in the staging of presumed pancreatic head and ampullary tumours. Br J Cancer 94 (2006), 213–217.
37. 37 Cleary, S.P., Gryfe, R., Guindi, M., Greig, P., Smith, L., Mackenzie, R., et al. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 198 (2004), 722–731.
38. 38 Klein, F., Jacob, D., Bahra, M., Pelzer, U., Puhl, G., Krannich, A., et al. Prognostic factors for long-term survival in patients with ampullary carcinoma: the results of a 15-year observation period after pancreaticoduodenectomy. HPB Surg World J Hepatic Pancreat Biliary Surg, 2014, 2014, 970234.
39. 39 Zhou, J., Zhang, Q., Li, P., Shan, Y., Zhao, D., Cai, J., Jaundice as a prognostic factor in patients undergoing radical treatment for carcinomas of the ampulla of vater. Chin Med J 127 (2014), 860–864.
40. 40 Papadoniou, N., Kosmas, C., Gennatas, K., Polyzos, A., MouratidoU, D., Skopelitis, E., et al. Prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. Anticancer Res 28 (2008), 543–549.
41. 41 Tas, F., Sen, F., Odabas, H., Kilic, L., Keskin, S., Yildiz, I., Performance status of patients is the major prognostic factor at all stages of pancreatic cancer. Int J Clin Oncol 18 (2013), 839–846.
42. 42 Okusaka, T., Okada, S., Ueno, H., Ikeda, M., Shimada, K., Yamamoto, J., et al. Abdominal pain in patients with resectable pancreatic cancer with reference to clinicopathologic findings. Pancreas 22 (2001), 279–284.
43. 43 Fitzgerald, P.J., The pathology of pancreatic cancer and its possible relationship to pain. J Pain Symptom Manag 3 (1988), 171–175.
44. 44 Kelsen, D.P., Portenoy, R., Thaler, H., Tao, Y., Brennan, M., Pain as a predictor of outcome in patients with operable pancreatic carcinoma. Surgery 122 (1997), 53–59.
45. 45 Ridder, G.J., Klempnauer, J., Back pain in patients with ductal pancreatic cancer – its impact on resectability and prognosis after resection. Scand J Gastroenterology 30 (1995), 1216–1220.
46. 46 Haas, M., Heinemann, V., Kullmann, F., Laubender, R.P., Klose, C., Bruns, C.J., et al. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol 139 (2013), 681–689.
47. 47 Alkhateeb, A., Zubritsky, L., Kinsman, B., Leitzel, K., Campbell-Baird, C., Ali, S.M., et al. Elevation in multiple serum inflammatory biomarkers predicts survival of pancreatic cancer patients with inoperable disease. J Gastrointest Cancer 45 (2014), 161–167.
48. 48 Miura, T., Hirano, S., Nakamura, T., Tanaka, E., Shichinohe, T., Tsuchikawa, T., et al. A new preoperative prognostic scoring system to predict prognosis in patients with locally advanced pancreatic body cancer who undergo distal pancreatectomy with en bloc celiac axis resection: a retrospective cohort study. Surgery 155 (2014), 457–467.
49. 49 Stotz, M., Gerger, A., Eisner, F., Szkandera, J., Loibner, H., Ress, A.L., et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer 109 (2013), 416–421.
50. 50 Smith, R.A., Bosonnet, L., Ghaneh, P., Sutton, R., Evans, J., Healey, P., et al. The platelet-lymphocyte ratio improves the predictive value of serum CA19-9 levels in determining patient selection for staging laparoscopy in suspected periampullary cancer. Surgery 143 (2008), 658–666.
51. 51 Slaar, A., Eshuis, W.J., van der Gaag, N.A., Nio, C.Y., Busch, O.R.C., van Gulik, T.M., et al. Predicting distant metastasis in patients with suspected pancreatic and periampullary tumors for selective use of staging laparoscopy. World J Surg 35 (2011), 2528–2534.
52. 52 Garcea, G., Cairns, V., Berry, D.P., Neal, C.P., Metcalfe, M.S., Dennison, A.R., Improving the diagnostic yield from staging laparoscopy for periampullary malignancies the value of preoperative inflammatory markers and radiological tumor size. Pancreas 41 (2012), 233–237.
53. 53 Fortner, J.G., Klimstra, D.S., Senie, R.T., Maclean, B.J., Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg 223 (1996), 147–153.
54. 54 Forssell, H., Wester, M., Akesson, K., Johansson, S., A proposed model for prediction of survival based on a follow-up study in unresectable pancreatic cancer. BMJ Open, 3, 2013, 6.
55. 55 Chiang, K.-C., Yeh, C.-N., Lee, W.-C., Jan, Y.-Y., Hwang, T.-L., Prognostic analysis of patients with pancreatic head adenocarcinoma less than 2 cm undergoing resection. World J Gastroenterol 15 (2009), 4305–4310.
56. 56 Shimada, K., Sakamoto, Y., Sano, T., Kosuge, T., Hiraoka, N., Reappraisal of the clinical significance of tumor size in patients with pancreatic ductal carcinoma. Pancreas 33 (2006), 233–239.
57. 57 de Jong, M.C., Li, F., Cameron, J.L., Wolfgang, C.L., Edil, B.H., Herman, J.M., et al. Re-evaluating the impact of tumor size on survival following pancreaticoduodenectomy for pancreatic adenocarcinoma. J Surg Oncol 103 (2011), 656–662.
58. 58 Agarwal, B., Correa, A.M., Ho, L., Survival in pancreatic carcinoma based on tumor size. Pancreas 36 (2008), E15–E20.
59. 59 Yoshida, T., Matsumoto, T., Morii, Y., Ishio, T., Kitano, S., Yamada, Y., et al. Staging with helical computed tomography and laparoscopy in pancreatic head cancer. Hepato-Gastroenterology 49 (2002), 1428–1431.
60. 60 Morganti, A.G., Brizi, M.G., Macchia, G., Sallustio, G., Costamagna, G., Alfieri, S., et al. The prognostic effect of clinical staging in pancreatic adenocarcinoma. Ann Surg Oncol 12 (2005), 145–151.
61. 61 Chiang, K.-C., Lee, C.-H., Yeh, C.-N., Ueng, S.-H., Hsu, J.-T., Yeh, T.-S., et al. A novel role of the tumor size in pancreatic cancer as an ancillary factor for predicting resectability. J Cancer Res Ther 10 (2014), 142–146.
62. 62 Artinyan, A., Soriano, P.A., Prendergast, C., Low, T., Ellenhorn, J.D.I., Kim, J., The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB 10 (2008), 371–376.
63. 63 Fernandez-del Castillo, C.L., Warshaw, A.L., Pancreatic cancer. Laparoscopic staging and peritoneal cytology. Surg Oncol Clin N Am 7 (1998), 135–142.
64. 64 Contreras, C.M., Stanelle, E.J., Mansour, J., Hinshaw, J.L., Rikkers, L.F., Rettammel, R., et al. Staging laparoscopy enhances the detection of occult metastases in patients with pancreatic adenocarcinoma. J Surg Oncol 100 (2009), 663–669.
65. 65 Shah, D., Fisher, W.E., Hodges, S.E., Wu, M.-F., Hilsenbeck, S.G., Brunicardi, C., Preoperative prediction of complete resection in pancreatic cancer. J Surg Res 147 (2008), 216–220.
66. 66 Satoi, S., Yanagimoto, H., Toyokawa, H., Inoue, K., Wada, K., Yamamoto, T., et al. Selective use of staging laparoscopy based on carbohydrate antigen 19-9 level and tumor size in patients with radiographically defined potentially or borderline resectable pancreatic cancer. Pancreas 40 (2011), 426–432.
67. 67 Velanovich, V., Wollner, I., Ajlouni, M., Staging laparoscopy promotes increased utilization of postoperative therapy for unresectable intra-abdominal malignancies. J Gastrointest Surg 4 (2000), 542–546.
68. 68 Jarnagin, W.R., Bodniewicz, J., Dougherty, E., Conlon, K., Blumgart, L.H., Fong, Y., A prospective analysis of staging laparoscopy in patients with primary and secondary hepatobiliary malignancies. J Gastrointest Surg 4 (2000), 34–42.
69. 69 Jimenez, R.E., Warshaw, A.L., Rattner, D.W., Willett, C.G., McGrath, D., del Castillo, C., Impact of laparoscopic staging in the treatment of pancreatic cancer. Arch Surg 135 (2000), 409–414.
70. 70 White, R.R., Paulson, E.K., Freed, K.S., Keogan, M.T., Hurwitz, H.I., Lee, C., et al. Staging of pancreatic cancer before and after neoadjuvant chemoradiation. J Gastrointest Surg 5 (2001), 626–633.
71. 71 Todd, K.E., Gloor, B., Lane, J.S., Isacoff, W.H., Reber, H.A., Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole. J Gastrointest Surg Off J Soc Surg Aliment Tract 2 (1998), 159–166.
72. 72 White, R.R., Hurwitz, H.I., Morse, M.A., Lee, C., Anscher, M.S., Paulson, E.K., et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 8 (2001), 758–765.
73. 73 Al-Haddad, M., Martin, J.K., Nguyen, J., Pungpapong, S., Raimondo, M., Woodward, T., et al. Vascular resection and reconstruction for pancreatic malignancy: a single center survival study. J Gastrointest Surg 11 (2007), 1168–1174.
74. 74 Schachter, P.P., Avni, Y., Shimonov, M., Gvirtz, G., Rosen, A., Czerniak, A., The impact of laparoscopy and laparoscopic ultrasonography on the management of pancreatic cancer. Arch Surg 135 (2000), 1303–1307.
75. 75 Jimenez, R.E., Warshaw, A.L., Fernandez-Del Castillo, C., Laparoscopy and peritoneal cytology in the staging of pancreatic cancer. J Hepato-Biliary-Pancreat Surg 7 (2000), 15–20.